ZURICH (Reuters) - Actelion, Europe's largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week.
Nine month sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH), rose 3 percent to 1.138 billion Swiss francs, while net profit was 304 million francs.
Actelion confirmed its forecast for core earnings to cross into the double-digit percentage range for 2013.
(Reporting by Alice Baghdjian and Caroline Copley)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp